ASXL1 represses retinoic acid receptor-mediated transcription through associating with HP1 and LSD1
about
Rapid-throughput skeletal phenotyping of 100 knockout mice identifies 9 new genes that determine bone strengthASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repressionAdditional sex comb-like (ASXL) proteins 1 and 2 play opposite roles in adipogenesis via reciprocal regulation of peroxisome proliferator-activated receptor {gamma}Epigenetic regulators and their impact on therapy in acute myeloid leukemiaNovel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome.Annual Clinical Updates in Hematological Malignancies: a continuing medical education series: polycythemia vera and essential thrombocythemia: 2011 update on diagnosis, risk-stratification, and management.Single nucleotide polymorphism array lesions, TET2, DNMT3A, ASXL1 and CBL mutations are present in systemic mastocytosis.The BAP1/ASXL2 Histone H2A Deubiquitinase Complex Regulates Cell Proliferation and Is Disrupted in Cancer.Mutations in epigenetic modifiers in the pathogenesis and therapy of acute myeloid leukemia.Additional sex combs-like 2 is required for polycomb repressive complex 2 binding at select targetsCBL, CBLB, TET2, ASXL1, and IDH1/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia.Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A.Knockdown of SALL4 Protein Enhances All-trans Retinoic Acid-induced Cellular Differentiation in Acute Myeloid Leukemia CellsFunctional and cancer genomics of ASXL family membersLoss of Asxl1 leads to myelodysplastic syndrome-like disease in miceUnraveling the molecular pathophysiology of myelodysplastic syndromes.Update on cytogenetic and molecular changes in myelodysplastic syndromes.Current findings for recurring mutations in acute myeloid leukemiaUnlocking Mendelian disease using exome sequencing.Molecular biology of myelodysplastic syndromes.Histone methylation in myelodysplastic syndromes.Mutations in epigenetic regulators in myelodysplastic syndromes.Chronic myelomonocytic leukemia and atypical chronic myeloid leukemia: novel pathogenetic lesions.Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases.Role of TET2 and ASXL1 mutations in the pathogenesis of myeloproliferative neoplasms.Molecular biology of Philadelphia-negative myeloproliferative neoplasmsThe ASXL-BAP1 axis: new factors in myelopoiesis, cancer and epigenetics.The genetic basis of phenotypic heterogeneity in myelodysplastic syndromes.Epigenetic alterations in acute myeloid leukemias.Reversible inhibitors of LSD1 as therapeutic agents in acute myeloid leukemia: clinical significance and progress to date.Lysine methylation of promoter-bound transcription factors and relevance to cancer.Unliganded progesterone receptor-mediated targeting of an RNA-containing repressive complex silences a subset of hormone-inducible genesMutations with epigenetic effects in myeloproliferative neoplasms and recent progress in treatment: Proceedings from the 5th International Post-ASH Symposium.BAALC expression: a suitable marker for prognostic risk stratification and detection of residual disease in cytogenetically normal acute myeloid leukemia.The JAK2 gene as a protagonist in chronic myeloproliferative neoplasms.Uses and abuses of JAK2 and MPL mutation tests in myeloproliferative neoplasms a paper from the 2010 William Beaumont hospital symposium on molecular pathology.Silencing of ASXL1 impairs the granulomonocytic lineage potential of human CD34⁺ progenitor cells.ASXL1 mutations are infrequent in young patients with primary acute myeloid leukemia and their detection has a limited role in therapeutic risk stratification.The leucine twenty homeobox (LEUTX) gene, which lacks a histone acetyltransferase domain, is fused to KAT6A in therapy-related acute myeloid leukemia with t(8;19)(p11;q13).
P2860
Q21563368-59BC407B-2563-4C71-93B1-EE7DCC7C92E5Q24296658-255065E5-DB28-4023-BA87-D1A5E21D91D0Q24305362-68122C7D-347C-48EB-AC22-C39E4C01F28FQ26765402-B369E409-D7F0-479D-981C-3CF353632B10Q27687464-79970278-3DBE-47F0-800E-94D13A55CFEAQ27851909-972BAA6B-45AA-4557-8CA4-125AEA92F6B7Q34166859-A6D3AD68-D246-4779-AD71-50F1255E6CCDQ34384728-6AA7342C-243A-4C5A-8951-3EF143F3D163Q34496129-D04E2E07-34F1-4884-B3C6-981AD034AC28Q34651312-5BB62F68-E721-4B1E-8DB6-5906174D0D0FQ34989584-2EE01449-9645-44A2-8AD4-F0BB0F99C3FEQ35030952-AFB07206-78B9-43E9-BCCB-25E78885A056Q35346433-87151885-AB2A-436F-8E41-365DF4667791Q35536200-75931170-CD6C-4212-8F27-9BF0618D0656Q37040682-16FC3814-5884-4FF9-A486-F919D9332D7CQ37512080-D8143A58-3A74-43F5-90E9-A323E490B01CQ37671806-0DAE51A3-8DF9-42A9-802D-F4EE01F6B574Q37923939-98755B57-BAA9-45AB-88AB-95482B545C38Q37932085-D78A6D10-56B9-4979-84FF-F33CA9F81B11Q37932636-829C8D7F-24A6-41F5-89C7-721239F00BCBQ37937809-57C9E3B3-B0FF-4C41-83A5-CA42F60EA046Q37961859-DDEA8CDC-8623-4540-9445-D6F43697AD99Q37974844-C54A9A14-A63F-4CB8-B7DB-DE74E6F14B4DQ37979958-E435F219-884B-47A3-9999-5D6D1856EEC0Q37995804-B7FC82DE-0CAA-462B-BF01-6DEB234DC9FEQ38046319-CC6B097E-6EB1-452A-861D-72B34F14BD03Q38050756-A6D39B5C-5C24-493F-BF43-ADD14450F9FFQ38059391-631FC28B-6B50-4C49-A8F2-8C15CD4A1E0CQ38061848-F512B19E-EE7D-43C5-8775-0AEA14007C80Q38264968-D1C9FD04-4A7F-4782-AA73-18C071FD9897Q38270780-9607DBC7-581E-4EB1-B09E-8FE271A7EE2EQ38706561-E820FF2F-C4F5-4519-9B96-486BAE99E386Q39148484-0EE35A7B-F698-4D3C-816D-4A080A1250D6Q40298579-C2AF55F2-25E5-43CB-9BDF-D4662DA3DC6DQ41885481-8AEEBFA1-E280-4B62-B16C-1D5DF3C8D454Q42133428-97FE83B9-6A6E-4201-BA9F-2001F2587084Q42870230-7B9B6A44-4245-48E2-9E30-D2DF7AEA49FEQ43767798-33C64700-70EF-4E81-B160-B25769545BADQ44113808-EA46498A-CAE8-4F95-A363-42783B31F105Q45625477-404034DA-D37E-42EF-80EE-4FC6AE33754A
P2860
ASXL1 represses retinoic acid receptor-mediated transcription through associating with HP1 and LSD1
description
2010 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունվարին հրատարակված գիտական հոդված
@hy
article publié dans la revue scientifique Journal of Biological Chemistry
@fr
artikull shkencor
@sq
artículu científicu espublizáu en 2010
@ast
im Januar 2010 veröffentlichter wissenschaftlicher Artikel
@de
scientific journal article
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в січні 2010
@uk
مقالة علمية (نشرت عام 2010)
@ar
name
ASXL1 represses retinoic acid ...... associating with HP1 and LSD1
@ast
ASXL1 represses retinoic acid ...... associating with HP1 and LSD1
@en
ASXL1 represses retinoic acid ...... associating with HP1 and LSD1
@nl
type
label
ASXL1 represses retinoic acid ...... associating with HP1 and LSD1
@ast
ASXL1 represses retinoic acid ...... associating with HP1 and LSD1
@en
ASXL1 represses retinoic acid ...... associating with HP1 and LSD1
@nl
prefLabel
ASXL1 represses retinoic acid ...... associating with HP1 and LSD1
@ast
ASXL1 represses retinoic acid ...... associating with HP1 and LSD1
@en
ASXL1 represses retinoic acid ...... associating with HP1 and LSD1
@nl
P2093
P2860
P356
P1476
ASXL1 represses retinoic acid ...... associating with HP1 and LSD1
@en
P2093
Eun-Joo Kim
Jung-Min Na
Myengmo Kang
Sang-Wang Lee
Soo-Jong Um
Ui-Hyun Park
Yang-Sook Cho
P2860
P356
10.1074/JBC.M109.065862
P407
P577
2010-01-01T00:00:00Z